EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Isoginkgetin targets PLEKHA5 and suppresses PI3K/AKT/mTOR signaling in esophageal squamous cell carcinoma

Yanxin Dong, Xuben Niu, Wenting Song, Jiale Zhang, Shun Xie, Qiu Li, Shouyin Di, Taiqian Gong, Boshi Fan

Frontiers in Pharmacology · 18.11.2026 · 17

DOI: 10.3389/fphar.2026.1873431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Yanxin Dong und 8 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim of the study This study investigated the antitumor activity of isoginkgetin (IGK), a biflavonoid derived from Ginkgo biloba L., in esophageal squamous cell carcinoma (ESCC).

Methods

CCK-8, colony formation, EdU incorporation, wound-healing, Transwell, and flow-cytometric assays were used to characterize IGK-induced phenotypes. Integrated transcriptomic and data-independent acquisition proteomic analyses were used for abundance-based molecular profiling, while targeted antibody-based phosphorylation-array profiling was analyzed as a separate signaling-activity layer. Molecular docking and 100-ns molecular dynamics simulations assessed binding plausibility. SPR quantified direct IGK-PLEKHA5 binding, CETSA assessed IGK-dependent PLEKHA5 thermal stabilization, PLEKHA5 -overexpression experiments tested functional relevance, and a nude-mouse subcutaneous xenograft model assessed in vivo antitumor activity and tolerability within the measured endpoints.

Results

IGK inhibited ESCC cell proliferation, colony formation, migration, and invasion and induced G2/M arrest and apoptosis. Transcriptomic and proteomic profiles primarily reflected broad changes in cell-cycle, DNA-repair, p53-associated, and stress-response programs. Targeted phosphorylation-array analysis and immunoblotting showed reduced AKT and mTOR phosphorylation, together with changes in MAPK/ERK, GSK3α, and CREB-related signals. Cross-platform analysis showed significantly reduced PLEKHA5 protein abundance, accompanied by a downward trend in PLEKHA5 transcript expression. SPR showed concentration-dependent IGK-PLEKHA5 binding with an apparent equilibrium dissociation constant (K D ) of 9.266 μM, and CETSA showed IGK-dependent thermal stabilization of PLEKHA5. PLEKHA5 overexpression partially restored malignant phenotypes and AKT/mTOR phosphorylation. In vivo , IGK reduced xenograft growth and intratumoral PLEKHA5, p-AKT, p-mTOR, and Ki-67 signals without overt renal injury or increases in the measured inflammatory markers under the tested schedule.

Conclusion

These findings support PLEKHA5 as a direct binding target of IGK and indicate that PLEKHA5 contributes to the attenuation of AKT/mTOR signaling and the antitumor response in ESCC. The partial rescue following PLEKHA5 overexpression further suggests that additional IGK-responsive mechanisms are also involved.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dong, Y., Niu, X., Song, W., Zhang, J., Xie, S., Li, Q., Di, S., Gong, T., & Fan, B. (2026). Isoginkgetin targets PLEKHA5 and suppresses PI3K/AKT/mTOR signaling in esophageal squamous cell carcinoma. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1873431

Vancouver

Dong Y, Niu X, Song W, Zhang J, Xie S, Li Q, et al. Isoginkgetin targets PLEKHA5 and suppresses PI3K/AKT/mTOR signaling in esophageal squamous cell carcinoma. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1873431

BibTeX
@article{Dong2026,
  author = {Dong, Yanxin and Niu, Xuben and Song, Wenting and Zhang, Jiale and Xie, Shun and Li, Qiu and Di, Shouyin and Gong, Taiqian and Fan, Boshi},
  title = {Isoginkgetin targets PLEKHA5 and suppresses PI3K/AKT/mTOR signaling in esophageal squamous cell carcinoma},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1873431}
}
Kostenlos starten →